- In documentary ‘Modern Whore,’ a former escort takes control of her own narrative Today 6:30 AM
- Cara Delevingne calls out Justin Bieber for ‘ranking’ wife Hailey’s friends Friday 9:07 PM
- Fans defend Jenna Marbles after some people claimed she mistreated her dogs in a recent video Friday 8:37 PM
- ‘Friends’ gets reunion special on HBO Max, fans go wild Friday 7:37 PM
- Why you should drop everything and start reading ‘Lore Olympus’ Friday 6:27 PM
- ‘Boogaloo’ memes are trying to organize a second civil war—and they’re spreading fast Friday 3:48 PM
- People are disturbed by these McDonald’s-scented candles Friday 3:47 PM
- Season 2 of ‘The Witcher’ is in production Friday 3:16 PM
- Here are some cringey billboards Bloomberg ran in Arizona Friday 2:51 PM
- PewDiePie returns to YouTube after 37-day hiatus Friday 2:01 PM
- Why was a Republican Party Facebook page co-managed by someone in Turkmenistan? Friday 1:26 PM
- The shorthand guide to ‘Star Wars: The Clone Wars’ Friday 1:07 PM
- Congress urges Tinder to screen for sex offenders Friday 1:03 PM
- Video shows 9-year-old threatening suicide after being bullied Friday 12:01 PM
- Ex-Goldman Sachs CEO says he might vote Trump because Sanders is too mean to him Friday 11:40 AM
Martin Shkreli arrested on charges of securities fraud
What goes around comes around.
The most hated man on the Internet may be going to prison.
Martin Shkreli, the 32-year-old CEO of Turing Pharmaceuticals who became infamous for boosting the price of a life-saving drug more than 5,000 percent, has been arrested by the FBI for securities fraud, reports Bloomberg News.
Shkreli’s arrest has nothing to do with price gouging, however. Instead, federal prosecutors have accused him of taking stock from a firm he founded in 2011, Retrophin Inc., and using the stock to pay off debt related to MSMB Capital Management, a hedge fund that collapsed after losing millions of dollars, as well as personal debt. Shkreli is also accused to misleading clients to get them to invest in two funds.
He first sparked the public’s wrath earlier this year after news that Turing jacked-up the price of Daraprim, a drug used to boost the immune systems of people with life-threatening illnesses like HIV, from $13.5 per pill to $750. He quickly became the face of corporate greed and a poster boy from everything that people feel is wrong with a capitalist system.
Adding to his villainous image, Shkreli later reneged on his promise to lower the price of Daraprim. It was later revealed that he was also the mystery person who purchase the only copy of Wu-Tang Clan’s album Once Upon a Time in Shaolin for “millions” of dollars.
If there is a curious gap in your favorite artist’s discography, well, now you know why.
— Martin Shkreli (@MartinShkreli) December 9, 2015
In a lawsuit filed in August, Retrophin accused Shkreli of a number of complex financial transactions that include poaching company funds in fraudulent transactions with investors in MSMB. The company also alleges that Shkreli used “fake consulting agreements,” as Bloomberg puts it, to pay off some MSMB investors, among other allegations of wrongdoing.
Writing on the investment forum Investorhub in February 2015, Shkreli shrugged off Retrophin’s allegations as “completely false, untrue at best and defamatory at worst.”
“I am confident that anyone who looked into the transactions would find them perfectly legal, reasonable and quite intelligent (the results of the company speak for themselves),” Shkreli added. “I welcome any scrutiny by any party and have faith any investigation will be resolved without issue—it would not be the first time and it won’t be the last that my moves have been looked at—this is not my first rodeo and I have too many scars to do something stupid.”
Shkreli, as well as a second defendant, attorney Evan Greebel, could face up to 20 years in prison, if convicted.
Adding to Shkreli’s legal woes, the New York Attorney General’s office launched an investigation into whether Turing intentionally impeded other companies in creating generic versions of Daraprim, which could be sold at a lower cost.
Later that month, Imprimis Pharmaceuticals Inc. began selling its own version of Daraprim for approximately $1 per pill.
Update 4:35pm CT, Dec. 17: Shkreli and another defendant, Evan Greebel, face up to 20 years in prison.
Screenshot via ABC News
Andrew Couts is the former editor of Layer 8, a section dedicated to the intersection of the Internet and the state—and the gaps in between. Prior to the Daily Dot, Couts served as features editor and features writer for Digital Trends, associate editor of TheWeek.com, and associate editor at Maxim magazine. When he’s not working, Couts can be found hiking with his German shepherds or blasting around on motorcycles.